B-cell receptor triggers drug sensitivity of primary CLL cells by controlling glucosylation of ceramides
Published 2012 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
B-cell receptor triggers drug sensitivity of primary CLL cells by controlling glucosylation of ceramides
Authors
Keywords
-
Journal
BLOOD
Volume 120, Issue 19, Pages 3978-3985
Publisher
American Society of Hematology
Online
2012-08-28
DOI
10.1182/blood-2012-05-431783
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia
- (2012) M. F. M. de Rooij et al. BLOOD
- Sphingolipid Metabolism Cooperates with BAK and BAX to Promote the Mitochondrial Pathway of Apoptosis
- (2012) Jerry E. Chipuk et al. CELL
- PCI-32765: a novel Bruton's tyrosine kinase inhibitor for the treatment of lymphoid malignancies
- (2012) Eric S Winer et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- GCS overexpression is associated with multidrug resistance of human HCT-8 colon cancer cells
- (2012) Min Song et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765
- (2011) S. E. M. Herman et al. BLOOD
- The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo
- (2011) S. Ponader et al. BLOOD
- The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia
- (2011) J. Hoellenriegel et al. BLOOD
- CAL-101: a phosphatidylinositol-3-kinase p110-delta inhibitor for the treatment of lymphoid malignancies
- (2011) Jorge J Castillo et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase I Study of Navitoclax in Patients With Relapsed or Refractory Disease
- (2011) Andrew W. Roberts et al. JOURNAL OF CLINICAL ONCOLOGY
- Ceramide and activated Bax act synergistically to permeabilize the mitochondrial outer membrane
- (2010) Vidyaramanan Ganesan et al. APOPTOSIS
- Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial
- (2010) P. Dreger et al. BLOOD
- Phosphatidylinositol 3-kinase- inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals
- (2010) S. E. M. Herman et al. BLOOD
- Therapeutic applications of bioactive sphingolipids in hematological malignancies
- (2010) Huseyin Atakan Ekiz et al. INTERNATIONAL JOURNAL OF CANCER
- Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial
- (2010) M Hallek et al. LANCET
- Glucosylceramide synthase inhibitors sensitise CLL cells to cytotoxic agents without reversing P-gp functional activity
- (2009) Gareth Gerrard et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Ceramide-induced cell death in malignant cells
- (2008) Alexander Carpinteiro et al. CANCER LETTERS
- A novel paradigm for rapid ABT-737-induced apoptosis involving outer mitochondrial membrane rupture in primary leukemia and lymphoma cells
- (2008) M Vogler et al. CELL DEATH AND DIFFERENTIATION
- Quantitative analysis of sphingolipids for lipidomics using triple quadrupole and quadrupole linear ion trap mass spectrometers
- (2008) Rebecca L. Shaner et al. JOURNAL OF LIPID RESEARCH
- Bioactive sphingolipids: metabolism and function
- (2008) Nana Bartke et al. JOURNAL OF LIPID RESEARCH
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started